We are live on ! Find out more
PVLA

Palvella Therapeutics
PVLA

180 hedge funds and large institutions have $1.65B invested in Palvella Therapeutics in 2026 Q1 according to their latest regulatory filings, with 65 funds opening new positions, 65 increasing their positions, 30 reducing their positions, and 21 closing their positions.

New
Increased
Maintained
Reduced
Closed

276% more call options, than puts

Call options by funds: $53.5M | Put options by funds: $14.2M

210% more first-time investments, than exits

New positions opened: 65 | Existing positions closed: 21

117% more repeat investments, than reductions

Existing positions increased: 65 | Existing positions reduced: 30

61% more capital invested

Capital invested by funds: $1.02B → $1.65B (+$626M)

50% more funds holding in top 10

Funds holding in top 10: 4 → 6 (+2)

29.57% more ownership

Funds ownership: 82.45% → 112.03% (+30%)

29% more funds holding

Funds holding: 140 → 180 (+40)

Holders
180
Holders Change
+40
Holders Change %
+28.57%
% of All Funds
2.22%
Holding in Top 10
6
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+50%
% of All Funds
0.07%
New
65
Increased
65
Reduced
30
Closed
21
Calls
$53.5M
Puts
$14.2M
Net Calls
+$39.3M
Net Calls Change
+$29.3M

Top Buyers

1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$41.6M
2
FCM
Frontier Capital Management
Massachusetts
+$39M
3
FLAM
First Light Asset Management
Minnesota
+$28.3M
4
SCM
Suvretta Capital Management
New York
+$27.2M
5
Jennison Associates
Jennison Associates
New York
+$26.4M

Top Sellers

1
SPPAM
Summit Partners Public Asset Management
Massachusetts
-$40.8M
2
PA
Perceptive Advisors
New York
-$27.9M
3
FAM
Fred Alger Management
New York
-$13.4M
4
Morgan Stanley
Morgan Stanley
New York
-$9.67M
5
SB
Samsara BioCapital
California
-$6.92M
Name Holding Trade Value Shares
Change 		Change in
Stake
TI
51
Trexquant Investment
Connecticut
$4.57M +$3.82M +36,639 New
WCM Investment Management
52
WCM Investment Management
California
$4.42M +$4.17M +39,964 New
Wellington Management Group
53
Wellington Management Group
Massachusetts
$4.24M +$1.21M +11,637 +52%
RA
54
Royce & Associates
New York
$3.93M +$156K +1,497 +5%
BOCH
55
Blue Owl Capital Holdings
New York
$3.9M -$939K -9,000 -22%
EI
56
EAM Investors
California
$3.66M +$3.06M +29,328 New
BNP Paribas Financial Markets
57
BNP Paribas Financial Markets
France
$3.46M +$2.85M +27,311 +5,811%
NIP
58
Nicholas Investment Partners
California
$3.44M +$2.88M +27,603 New
Raymond James Financial
59
Raymond James Financial
Florida
$3.17M +$332K +3,182 +14%
Adage Capital Partners
60
Adage Capital Partners
Massachusetts
$3.12M +$2.61M +25,000 New
Nomura Holdings
61
Nomura Holdings
Japan
$2.99M +$2.5M +24,008 New
Charles Schwab
62
Charles Schwab
California
$2.86M +$139K +1,337 +6%
TD Asset Management
63
TD Asset Management
Ontario, Canada
$2.84M +$2.37M +22,746 New
FAM
64
Fred Alger Management
New York
$2.65M -$13.4M -128,790 -86%
New York State Common Retirement Fund
65
New York State Common Retirement Fund
New York
$2.64M +$399K +3,827 +22%
N
66
Nuveen
North Carolina
$2.6M +$131K +1,258 +6%
Citadel Advisors
67
Citadel Advisors
Florida
$2.55M +$1.86M +17,836 +677%
ECM
68
ExodusPoint Capital Management
New York
$2.53M +$2.12M +20,277 New
BCM
69
BlueCrest Capital Management
Jersey
$2.49M +$2.09M +20,000 New
Fifth Third Bancorp
70
Fifth Third Bancorp
Ohio
$2.49M +$2.08M +19,947 New
Swiss National Bank
71
Swiss National Bank
Switzerland
$2.42M +$542K +5,200 +37%
BFM
72
Boothbay Fund Management
New York
$2.36M +$1.98M +18,962 New
Susquehanna International Group
73
Susquehanna International Group
Pennsylvania
$2.34M +$1.96M +18,808 New
Bank of New York Mellon
74
Bank of New York Mellon
New York
$2.25M +$185K +1,777 +11%
Renaissance Technologies
75
Renaissance Technologies
New York
$2.24M -$476K -4,560 -20%
1 2
3
4 5

PVLA Hedge Fund Activity: Q1 2026 in Review

180 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Palvella Therapeutics (PVLA) for Q1 2026, worth a combined $1.65B — up 61% from $1.02B a quarter earlier.

Buyers outnumbered sellers: 65 funds opened new PVLA positions and 21 closed out — a net gain of 44 holders — while 65 added to existing stakes and 30 trimmed.

The largest buyer was T. Rowe Price Associates, adding an estimated $41.6M. The largest seller was Summit Partners Public Asset Management, exiting entirely with an estimated $40.8M sold.

  • 180 institutional investors held Palvella Therapeutics (PVLA) as of Q1 2026, up from 140 in Q4 2025.
  • Funds reported $1.65B of Palvella Therapeutics stock for Q1 2026, up 61% quarter-over-quarter.
  • 65 funds opened new Palvella Therapeutics positions in Q1 2026 and 21 closed out, a net change of +44 holders.
  • The largest Palvella Therapeutics buyer in Q1 2026 was T. Rowe Price Associates, an estimated $41.6M added.
  • The largest Palvella Therapeutics seller in Q1 2026 was Summit Partners Public Asset Management, an estimated $40.8M sold.

Based on aggregated 13F filings for Q1 2026.